Log in to search using one of your social media accounts:

 

Chemoradiotherapy Remains Standard of Care in Cervical Cancer Chemoradiotherapy Remains Standard of Care in Cervical Cancer
Chemoradiotherapy remains the standard of care for cervical cancer patients with locally advanced disease, concludes an Indian trial that compared it to neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study confirms chemoradiation is best treatment for locally advanced cervical cancer
(European Society for Medical Oncology) A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid. The trial demonstrated no improved disease-free survival with neoadjuvant chemotherapy followed by surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

CT Abnormality in Patient With Stage II Breast Cancer History
A 57-year-old woman with a history of stage IIB breast cancer (ypT2N1M0) status post neoadjuvant chemotherapy and left partial mastectomy presents to the radiation oncology clinic for CT simulation in preparation for breast radiotherapy. Noncontrast CT scan incidentally found the abnormality depicted with arrows below. (Source: CancerNetwork)
Source: CancerNetwork - September 8, 2017 Category: Cancer & Oncology Authors: Joseph Miccio, MD Tags: Image IQ Source Type: news

Cynvenio and Saint Luke ’s Cancer Institute Launch Pilot Study to...
New Study will use LiquidBiopsy® ClearID® testing and NK Score™ natural killer cell activity testing to monitor breast cancer patients following neoadjuvant chemotherapy.(PRWeb August 17, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14601181.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 17, 2017 Category: Pharmaceuticals Source Type: news

Urothelial Cancer Response to Neoadjuvant Chemo Varies by Histologic Variant
Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that capecitabine adjuvant therapy may improve survival in women with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2017 Category: Consumer Health News Source Type: news

Rectal Cancer Response to Preop Tx Doesn't Rule Out Nodal Disease Rectal Cancer Response to Preop Tx Doesn't Rule Out Nodal Disease
Rectal cancer patients who have a complete clinical response (ypT0) to neoadjuvant chemoradiation (NCR) may still have nodal disease, according to new research.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Chemo Prior to CRT in Nasopharyngeal Carcinoma May Improve Outcomes
The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Head & Neck Cancer News Source Type: news

Many TNBC Patients Unnecessarily Opt for Mastectomy
The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Breast Cancer News Triple-Negative Breast Cancer Source Type: news

COUNTERPOINT: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
In a Significant Percentage of Patients, Neoadjuvant Therapy Yields Equivalent Survival, With Better Quality of Life and Lower Costs (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2017 Category: Cancer & Oncology Authors: Anna Fagotti, MD, PhD Giovanni Scambia, MD Tags: Gynecologic Cancers Oncology Journal Ovarian Cancer Source Type: news

POINT: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
Cytoreductive Surgery Is the Best Way to Affect Survival Outcomes (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2017 Category: Cancer & Oncology Source Type: news

Adjuvant Capecitabine Improves Survival in Residual Invasive Breast Cancer
Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news

Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer
Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Ovarian Cancer News Source Type: news

Treatment of Low-Lying Early Rectal Cancer
This video examines the treatment of patients with low-lying rectal cancer and explores options such as neoadjuvant chemoradiotherapy, which could improve the efficacy of surgery. (Source: CancerNetwork)
Source: CancerNetwork - May 25, 2017 Category: Cancer & Oncology Authors: Julio Garcia-Aguilar, MD, PhD Tags: Videos Gastrointestinal Cancers Source Type: news

Watch-and-Wait for Some Rectal Cancer Patients After Chemoradiation Watch-and-Wait for Some Rectal Cancer Patients After Chemoradiation
Among patients with locally advanced rectal cancer who have a clinical complete response to neoadjuvant chemoradiation, most will not experience tumor regrowth and may avoid radical surgery when a wait-and-watch approach is used, new research suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 22, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Dateline City: KENILWORTH, N.J. Now Approved for First-Line Treatment in Patients Ineligible for Cisplatin-Containing Chemotherapy and Second-Line Treatment in Patients Who Have Disease Progression During or Following Platinum-Containing Chemotherapy or Within 12 Months of Neoadjuvant or Adjuvant Treatment with Platinum-Containing Chemotherapy KEYTRUDA is the Only Anti-PD-1 Therapy to Demonstrate Superior Overall Survival Versus Chemotherapy in Patients With Advanced Urothelial Carcinoma Post-Platinum FailureKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,...
Source: Merck.com - Product News - May 18, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news

New VTE Often Occurs During Chemo in Ovarian Cancer
Most cases of venous thromboembolism occurred during neoadjuvant or adjuvant chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 11, 2017 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Nursing, Oncology, Surgery, Journal, Source Type: news

Pathologic complete response to neoadjuvant therapy in certain breast cancer patients predicts low risk for local metastases
(University of Texas M. D. Anderson Cancer Center) Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center. The study, published today in JAMA Surgery, identifies the exceptional responders who are at lowest risk for local metastases and thereby are candidates for less invasive treatment options. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2017 Category: Cancer & Oncology Source Type: news

Residual Disease Prognostic for Breast Cancer Survival (CME/CE)
(MedPage Today) -- Index may predict success of neoadjuvant chemotherapy (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 6, 2017 Category: OBGYN Source Type: news

A New Trend in Pancreatic Cancer Treatment A New Trend in Pancreatic Cancer Treatment
Neoadjuvant chemotherapy is now being used in various centers for select patients. And clinical trials are pushing the presurgery chemo envelope in patients who are'borderline'candidates for surgery. Here's why.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 30, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Novel Calculator Guides Treatment Choice in Esophageal Cancer
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news

Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Novel calculator more easily identifies patients who will benefit from neoadjuvant chemoradiation
A calculator to guide treatment choice in esophageal cancer has been developed by a team of researchers. The tool helps identify which patients may benefit from treatment before surgery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 2, 2017 Category: Science Source Type: news

Optimizing Outcomes for Patients With Curable Bladder Cancer
This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2017 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Tags: ASCO Genitourinary Cancers Symposium Videos Genitourinary Cancers Source Type: news

Genomic Subtyping Could Guide Treatment Decisions for Bladder Cancer
Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study. (Source: CancerNetwork)
Source: CancerNetwork - February 19, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium Bladder Cancer News Source Type: news

Esophageal cancer: Loss of muscle mass represents a significant risk to survival
Esophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia, new research concludes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 14, 2017 Category: Science Source Type: news

Bioselective Treatment Improves Survival in Advanced Laryngeal Cancer Bioselective Treatment Improves Survival in Advanced Laryngeal Cancer
Tumor response to a single cycle of neoadjuvant chemotherapy helps pinpoint appropriate treatment for patients with advanced laryngeal cancer, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Residual Cancer Burden Prognostic Across Breast Cancer Phenotypes
Residual cancer burden was found to be prognostic for long-term survival following neoadjuvant chemotherapy for three phenotypic subsets of breast cancer in a new single-institution study. (Source: CancerNetwork)
Source: CancerNetwork - February 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

More Data Needed on Watch-and-Wait Strategy for Rectal Cancer
Using a watch-and-wait strategy among a group of highly selected patients with rectal cancer who have undergone neoadjuvant chemoradiation did not appear to compromise outcomes. (Source: CancerNetwork)
Source: CancerNetwork - January 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Conference Report Source Type: news

FDA grants Roche ’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are ineligible for cisplatin chemotherapy, and are either previously untreated (first-line) or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). (Source: Roche Media News)
Source: Roche Media News - January 9, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are ineligible for cisplatin chemotherapy, and are either previously untreated (first-line) or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). (Source: Roche Investor Update)
Source: Roche Investor Update - January 9, 2017 Category: Pharmaceuticals Source Type: news

AI Neither Adds nor Detracts From Chemo in This Setting AI Neither Adds nor Detracts From Chemo in This Setting
The addition of endocrine deprivation therapy to neoadjuvant chemotherapy doesn't increase pathologic complete response rates in hormone receptor-positive, HER2-positive breast cancer, but it doesn't diminish the effectiveness of chemotherapy either, as has long been believed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Scalp-Cooling System Reduced Hair Loss From Breast Cancer Chemotherapy
With the help of a scalp-cooling device, 50% of women with breast cancer undergoing neoadjuvant or adjuvant chemotherapy were able to prevent hair loss, according to the results of the SCALP trial. (Source: CancerNetwork)
Source: CancerNetwork - December 10, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Conferences/SABCS 2016 Source Type: news

Image-guided biopsy identifies patients who achieve pathologic complete response after neoadjuvant therapy
In a pilot study, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 9, 2016 Category: Science Source Type: news

Image-guided biopsy identifies patients who achieve pathologic complete response after neoadjuvant therapy
(University of Texas M. D. Anderson Cancer Center) In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2016 Category: Cancer & Oncology Source Type: news

No Benefit in Adding AI to Neoadjuvant Treatment for HR+/HER2+ Breast Cancer
The addition of estrogen deprivation to neoadjuvant chemotherapy did not significantly affect pathologic complete response in women with HR-positive, HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: HER2-Positive Breast Cancer News Conferences/SABCS 2016 Source Type: news

Some breast cancer patients on neoadjuvant chemo may avoid axillary lymph node dissection
(American Association for Cancer Research) Axillary lymph node dissection could be avoided by certain early-stage breast cancer patients receiving neoadjuvant chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2016 Category: Cancer & Oncology Source Type: news

Primary Surgery Tops Neoadjuvant Chemo in Epithelial Ovarian Cancer?
A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

Primary Cytoreductive Surgery: Improved Survival in Ovarian Cancer Primary Cytoreductive Surgery: Improved Survival in Ovarian Cancer
Otherwise healthy women with advanced-stage epithelial ovarian cancer who undergo primary cytoreductive surgery (PCS) have improved survival compared with those who receive neoadjuvant chemotherapy (NACT), according to Boston-based researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 29, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Presurgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancer
(Massachusetts General Hospital) Neoadjuvant endocrine therapy -- designed to reduce the size of breast tumors before surgical removal -- appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast cancer with considerably fewer side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2016 Category: Cancer & Oncology Source Type: news

Surgery timing after neoadjuvant chemoradiation in Stage IIIA NSCLC impacts OS
(International Association for the Study of Lung Cancer) The timing of surgery after neoadjuvant chemoradiation in patients with stage IIIA non-small cell lung cancer affects the overall survival of patients receiving trimodality therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2016 Category: Cancer & Oncology Source Type: news

Longer Gap Between Chemo, Esophageal Resection Tied to Better Response Longer Gap Between Chemo, Esophageal Resection Tied to Better Response
In patients with esophageal cancer, increasing the interval between neoadjuvant chemoradiotherapy and resection beyond six weeks is associated with better odds of pathologic complete response, according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 26, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Tx Tops Surgery for Pancreatic Ca (CME/CE)
(MedPage Today) -- Chemo improved survival versus surgery and adjuvant therapy in newly diagnosed patients (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 16, 2016 Category: Gastroenterology Source Type: news

Neoadjuvant Chemo Favored in Advanced Ovarian Cancer Neoadjuvant Chemo Favored in Advanced Ovarian Cancer
The use of neoadjuvant chemotherapy is increasing for the treatment of advanced ovarian cancer, and is being favored over surgery.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 9, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Better Survival With Surgery in Stage IIIC Ovarian Cancer
Over a 10-year period, the use of neoadjuvant chemotherapy increased significantly in women with advanced ovarian cancer, according to a new observational study. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

ASCO & SGO: Neoadjuvant Chemo Now a Standard for Ovarian Cancer ASCO & SGO: Neoadjuvant Chemo Now a Standard for Ovarian Cancer
Two major oncology professional societies have now come out in support of a role for neoadjuvant chemotherapy for ovarian cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 30, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

ASCO, SGO Clarify Chemo Role in Ovarian Cancer (CME/CE)
(MedPage Today) -- High clinical risk, low surgical success favor neoadjuvant therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 10, 2016 Category: Hematology Source Type: news

Neoadjuvant Chemo for Ovarian Ca Highlighted in New Guidelines Neoadjuvant Chemo for Ovarian Ca Highlighted in New Guidelines
Joint guidelines on the preferred treatment for advanced ovarian and related cancers aim to improve the quality of care for women with stage IIIC and IV invasive disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news